Survival of gastric cancer with concomitant liver metastases

Ching Ming Kwok, Chew Wun Wu, Su Shun Lo, King Han Shen, Mao-Chih Hsieh, Wing Yiu Lui

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Background/Aims: Prognosis of gastric cancer with concomitant liver metastasis is poor. Gastrectomy and chemotherapy had been reported to be beneficial to this group of patients. Whether all the patients can benefit from that treatment modality and whether the clinical characteristics can give some information about survival have not been evaluated. Methodology: Eighty-three gastric cancer patients with concomitant liver metastases who had received treatment in the past 10 years were retrospectively studied with special reference to different extent of liver metastases. Clinical characteristics (peritoneal tumor dissemination, tumor markers, clinicopathological factors), treatment modalities (gastrectomy or chemotherapy) and survival were analyzed for their possible relationship with the extent of liver metastases. Results: There were 33 patients with liver metastases limited to one lobe and 50 patients had metastases in both lobes. The clinicopathological characteristics show no difference between uni- and bilobar liver metastases except higher percentage of concomitant peritoneal dissemination in patients with bilobar disease. More unilobar involvement patients underwent gastrectomy (70% vs. 48%, p = 0.018). Higher frequency of abnormal CEA level in bilobar metastases (38% vs. 60%, p = 0.045). Median survival of unilobar metastasis is 7.8 months and 4.3 months for the bilobar involvement (p = 0.001). Gastrectomy might prolong the survival in patients with unilobar metastasis (p = 0.005), but not in patients with bilobar diseases (p = 0.074). Chemotherapy could prolong the survival in patients without gastrectomy, but not the survival after gastrectomy. Conclusions: The clinicopathological characteristics and tumor markers have no role in predicting the survival among patients with liver metastases. Both gastrectomy and chemotherapy for the patients without gastrectomy could prolong survival, but chemotherapy could not prolong the survival after gastrectomy, the benefit of resection and chemotherapy are probably caused by selection bias.

Original languageEnglish
Pages (from-to)1527-1530
Number of pages4
JournalHepato-Gastroenterology
Volume51
Issue number59
Publication statusPublished - Sep 1 2004
Externally publishedYes

Fingerprint

Stomach Neoplasms
Gastrectomy
Neoplasm Metastasis
Survival
Liver
Drug Therapy
Tumor Biomarkers
Selection Bias
Therapeutics

Keywords

  • Gastric cancer
  • Liver metastasis
  • Survival

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Kwok, C. M., Wu, C. W., Lo, S. S., Shen, K. H., Hsieh, M-C., & Lui, W. Y. (2004). Survival of gastric cancer with concomitant liver metastases. Hepato-Gastroenterology, 51(59), 1527-1530.

Survival of gastric cancer with concomitant liver metastases. / Kwok, Ching Ming; Wu, Chew Wun; Lo, Su Shun; Shen, King Han; Hsieh, Mao-Chih; Lui, Wing Yiu.

In: Hepato-Gastroenterology, Vol. 51, No. 59, 01.09.2004, p. 1527-1530.

Research output: Contribution to journalArticle

Kwok, CM, Wu, CW, Lo, SS, Shen, KH, Hsieh, M-C & Lui, WY 2004, 'Survival of gastric cancer with concomitant liver metastases', Hepato-Gastroenterology, vol. 51, no. 59, pp. 1527-1530.
Kwok CM, Wu CW, Lo SS, Shen KH, Hsieh M-C, Lui WY. Survival of gastric cancer with concomitant liver metastases. Hepato-Gastroenterology. 2004 Sep 1;51(59):1527-1530.
Kwok, Ching Ming ; Wu, Chew Wun ; Lo, Su Shun ; Shen, King Han ; Hsieh, Mao-Chih ; Lui, Wing Yiu. / Survival of gastric cancer with concomitant liver metastases. In: Hepato-Gastroenterology. 2004 ; Vol. 51, No. 59. pp. 1527-1530.
@article{e3bb68b8b594438fba99768789d1985a,
title = "Survival of gastric cancer with concomitant liver metastases",
abstract = "Background/Aims: Prognosis of gastric cancer with concomitant liver metastasis is poor. Gastrectomy and chemotherapy had been reported to be beneficial to this group of patients. Whether all the patients can benefit from that treatment modality and whether the clinical characteristics can give some information about survival have not been evaluated. Methodology: Eighty-three gastric cancer patients with concomitant liver metastases who had received treatment in the past 10 years were retrospectively studied with special reference to different extent of liver metastases. Clinical characteristics (peritoneal tumor dissemination, tumor markers, clinicopathological factors), treatment modalities (gastrectomy or chemotherapy) and survival were analyzed for their possible relationship with the extent of liver metastases. Results: There were 33 patients with liver metastases limited to one lobe and 50 patients had metastases in both lobes. The clinicopathological characteristics show no difference between uni- and bilobar liver metastases except higher percentage of concomitant peritoneal dissemination in patients with bilobar disease. More unilobar involvement patients underwent gastrectomy (70{\%} vs. 48{\%}, p = 0.018). Higher frequency of abnormal CEA level in bilobar metastases (38{\%} vs. 60{\%}, p = 0.045). Median survival of unilobar metastasis is 7.8 months and 4.3 months for the bilobar involvement (p = 0.001). Gastrectomy might prolong the survival in patients with unilobar metastasis (p = 0.005), but not in patients with bilobar diseases (p = 0.074). Chemotherapy could prolong the survival in patients without gastrectomy, but not the survival after gastrectomy. Conclusions: The clinicopathological characteristics and tumor markers have no role in predicting the survival among patients with liver metastases. Both gastrectomy and chemotherapy for the patients without gastrectomy could prolong survival, but chemotherapy could not prolong the survival after gastrectomy, the benefit of resection and chemotherapy are probably caused by selection bias.",
keywords = "Gastric cancer, Liver metastasis, Survival",
author = "Kwok, {Ching Ming} and Wu, {Chew Wun} and Lo, {Su Shun} and Shen, {King Han} and Mao-Chih Hsieh and Lui, {Wing Yiu}",
year = "2004",
month = "9",
day = "1",
language = "English",
volume = "51",
pages = "1527--1530",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "59",

}

TY - JOUR

T1 - Survival of gastric cancer with concomitant liver metastases

AU - Kwok, Ching Ming

AU - Wu, Chew Wun

AU - Lo, Su Shun

AU - Shen, King Han

AU - Hsieh, Mao-Chih

AU - Lui, Wing Yiu

PY - 2004/9/1

Y1 - 2004/9/1

N2 - Background/Aims: Prognosis of gastric cancer with concomitant liver metastasis is poor. Gastrectomy and chemotherapy had been reported to be beneficial to this group of patients. Whether all the patients can benefit from that treatment modality and whether the clinical characteristics can give some information about survival have not been evaluated. Methodology: Eighty-three gastric cancer patients with concomitant liver metastases who had received treatment in the past 10 years were retrospectively studied with special reference to different extent of liver metastases. Clinical characteristics (peritoneal tumor dissemination, tumor markers, clinicopathological factors), treatment modalities (gastrectomy or chemotherapy) and survival were analyzed for their possible relationship with the extent of liver metastases. Results: There were 33 patients with liver metastases limited to one lobe and 50 patients had metastases in both lobes. The clinicopathological characteristics show no difference between uni- and bilobar liver metastases except higher percentage of concomitant peritoneal dissemination in patients with bilobar disease. More unilobar involvement patients underwent gastrectomy (70% vs. 48%, p = 0.018). Higher frequency of abnormal CEA level in bilobar metastases (38% vs. 60%, p = 0.045). Median survival of unilobar metastasis is 7.8 months and 4.3 months for the bilobar involvement (p = 0.001). Gastrectomy might prolong the survival in patients with unilobar metastasis (p = 0.005), but not in patients with bilobar diseases (p = 0.074). Chemotherapy could prolong the survival in patients without gastrectomy, but not the survival after gastrectomy. Conclusions: The clinicopathological characteristics and tumor markers have no role in predicting the survival among patients with liver metastases. Both gastrectomy and chemotherapy for the patients without gastrectomy could prolong survival, but chemotherapy could not prolong the survival after gastrectomy, the benefit of resection and chemotherapy are probably caused by selection bias.

AB - Background/Aims: Prognosis of gastric cancer with concomitant liver metastasis is poor. Gastrectomy and chemotherapy had been reported to be beneficial to this group of patients. Whether all the patients can benefit from that treatment modality and whether the clinical characteristics can give some information about survival have not been evaluated. Methodology: Eighty-three gastric cancer patients with concomitant liver metastases who had received treatment in the past 10 years were retrospectively studied with special reference to different extent of liver metastases. Clinical characteristics (peritoneal tumor dissemination, tumor markers, clinicopathological factors), treatment modalities (gastrectomy or chemotherapy) and survival were analyzed for their possible relationship with the extent of liver metastases. Results: There were 33 patients with liver metastases limited to one lobe and 50 patients had metastases in both lobes. The clinicopathological characteristics show no difference between uni- and bilobar liver metastases except higher percentage of concomitant peritoneal dissemination in patients with bilobar disease. More unilobar involvement patients underwent gastrectomy (70% vs. 48%, p = 0.018). Higher frequency of abnormal CEA level in bilobar metastases (38% vs. 60%, p = 0.045). Median survival of unilobar metastasis is 7.8 months and 4.3 months for the bilobar involvement (p = 0.001). Gastrectomy might prolong the survival in patients with unilobar metastasis (p = 0.005), but not in patients with bilobar diseases (p = 0.074). Chemotherapy could prolong the survival in patients without gastrectomy, but not the survival after gastrectomy. Conclusions: The clinicopathological characteristics and tumor markers have no role in predicting the survival among patients with liver metastases. Both gastrectomy and chemotherapy for the patients without gastrectomy could prolong survival, but chemotherapy could not prolong the survival after gastrectomy, the benefit of resection and chemotherapy are probably caused by selection bias.

KW - Gastric cancer

KW - Liver metastasis

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=3343004650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3343004650&partnerID=8YFLogxK

M3 - Article

C2 - 15362793

AN - SCOPUS:3343004650

VL - 51

SP - 1527

EP - 1530

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 59

ER -